High density lipoprotein complexes as delivery vehicles for anticancer drugs

Andras G. Lacko, Maya P. Nair, Sulabha Paranjape, Shemedia Johnson, Walter J. McConathy

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Materials and Methods: Recombinant high density lipoprotein (rHDL) particles were prepared with defined composition (phosphatidylcholine, apolipoprotein A-1, cholesterol and cholesteryl esters) and a molecular weight of approximately 187,000 kdaltons. Three molecules of taxol per rHDL particle were incorporated into these rHDL complexes. Results: Cholesteryl ester and taxol (HDL core components,) were taken up efficiently by several cancer cell lines compared to transformed normal ovarian cells (HGL5) used as the control. Immunoblotting with the scavenger receptor (SR-B1) antibody revealed strong immunoreactivity of several cancer cell lines. Conclusion: Our studies indicated that rHDL complexes can be used as efficient drug delivery vehicles due to the ability of cancer cells to acquire HDL core components. Targeting of anticancer drugs as components of the rHDL complex could result in reduction of toxic side-effects during chemotherapy.

Original languageEnglish
Pages (from-to)2045-2049
Number of pages5
JournalAnticancer Research
Volume22
Issue number4
StatePublished - 19 Aug 2002

Fingerprint

HDL Lipoproteins
Pharmaceutical Preparations
Cholesterol Esters
Paclitaxel
Scavenger Receptors
Cell Line
Neoplasms
Poisons
Apolipoprotein A-I
Drug Delivery Systems
Phosphatidylcholines
Immunoblotting
Molecular Weight
Drug Therapy
Antibodies

Keywords

  • Anticancer drug delivery
  • Lipoprotein complexes

Cite this

Lacko, Andras G. ; Nair, Maya P. ; Paranjape, Sulabha ; Johnson, Shemedia ; McConathy, Walter J. / High density lipoprotein complexes as delivery vehicles for anticancer drugs. In: Anticancer Research. 2002 ; Vol. 22, No. 4. pp. 2045-2049.
@article{46cc3b1a648b4bb39c3a8fc574d78fd1,
title = "High density lipoprotein complexes as delivery vehicles for anticancer drugs",
abstract = "Materials and Methods: Recombinant high density lipoprotein (rHDL) particles were prepared with defined composition (phosphatidylcholine, apolipoprotein A-1, cholesterol and cholesteryl esters) and a molecular weight of approximately 187,000 kdaltons. Three molecules of taxol per rHDL particle were incorporated into these rHDL complexes. Results: Cholesteryl ester and taxol (HDL core components,) were taken up efficiently by several cancer cell lines compared to transformed normal ovarian cells (HGL5) used as the control. Immunoblotting with the scavenger receptor (SR-B1) antibody revealed strong immunoreactivity of several cancer cell lines. Conclusion: Our studies indicated that rHDL complexes can be used as efficient drug delivery vehicles due to the ability of cancer cells to acquire HDL core components. Targeting of anticancer drugs as components of the rHDL complex could result in reduction of toxic side-effects during chemotherapy.",
keywords = "Anticancer drug delivery, Lipoprotein complexes",
author = "Lacko, {Andras G.} and Nair, {Maya P.} and Sulabha Paranjape and Shemedia Johnson and McConathy, {Walter J.}",
year = "2002",
month = "8",
day = "19",
language = "English",
volume = "22",
pages = "2045--2049",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

Lacko, AG, Nair, MP, Paranjape, S, Johnson, S & McConathy, WJ 2002, 'High density lipoprotein complexes as delivery vehicles for anticancer drugs', Anticancer Research, vol. 22, no. 4, pp. 2045-2049.

High density lipoprotein complexes as delivery vehicles for anticancer drugs. / Lacko, Andras G.; Nair, Maya P.; Paranjape, Sulabha; Johnson, Shemedia; McConathy, Walter J.

In: Anticancer Research, Vol. 22, No. 4, 19.08.2002, p. 2045-2049.

Research output: Contribution to journalArticle

TY - JOUR

T1 - High density lipoprotein complexes as delivery vehicles for anticancer drugs

AU - Lacko, Andras G.

AU - Nair, Maya P.

AU - Paranjape, Sulabha

AU - Johnson, Shemedia

AU - McConathy, Walter J.

PY - 2002/8/19

Y1 - 2002/8/19

N2 - Materials and Methods: Recombinant high density lipoprotein (rHDL) particles were prepared with defined composition (phosphatidylcholine, apolipoprotein A-1, cholesterol and cholesteryl esters) and a molecular weight of approximately 187,000 kdaltons. Three molecules of taxol per rHDL particle were incorporated into these rHDL complexes. Results: Cholesteryl ester and taxol (HDL core components,) were taken up efficiently by several cancer cell lines compared to transformed normal ovarian cells (HGL5) used as the control. Immunoblotting with the scavenger receptor (SR-B1) antibody revealed strong immunoreactivity of several cancer cell lines. Conclusion: Our studies indicated that rHDL complexes can be used as efficient drug delivery vehicles due to the ability of cancer cells to acquire HDL core components. Targeting of anticancer drugs as components of the rHDL complex could result in reduction of toxic side-effects during chemotherapy.

AB - Materials and Methods: Recombinant high density lipoprotein (rHDL) particles were prepared with defined composition (phosphatidylcholine, apolipoprotein A-1, cholesterol and cholesteryl esters) and a molecular weight of approximately 187,000 kdaltons. Three molecules of taxol per rHDL particle were incorporated into these rHDL complexes. Results: Cholesteryl ester and taxol (HDL core components,) were taken up efficiently by several cancer cell lines compared to transformed normal ovarian cells (HGL5) used as the control. Immunoblotting with the scavenger receptor (SR-B1) antibody revealed strong immunoreactivity of several cancer cell lines. Conclusion: Our studies indicated that rHDL complexes can be used as efficient drug delivery vehicles due to the ability of cancer cells to acquire HDL core components. Targeting of anticancer drugs as components of the rHDL complex could result in reduction of toxic side-effects during chemotherapy.

KW - Anticancer drug delivery

KW - Lipoprotein complexes

UR - http://www.scopus.com/inward/record.url?scp=0036332185&partnerID=8YFLogxK

M3 - Article

C2 - 12174882

AN - SCOPUS:0036332185

VL - 22

SP - 2045

EP - 2049

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -